Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 1.00 |
| ▸ | LTB4R | Q15722 | 5/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9431167 | 0.89 | NR1H4 (1.00) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7751099 | 0.86 | LTB4R (1.00) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL8652398 | 0.86 | LTB4R (0.85) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL8651177 | 0.85 | LTB4R (0.83) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL8653365 | 0.85 | LTB4R (0.86) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL8655402 | 0.85 | LTB4R (0.98) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9430782 | 0.85 | LTB4R (0.98) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9431492 | 0.85 | LTB4R (0.86) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9431503 | 0.85 | LTB4R (0.86) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9430787 | 0.85 | LTB4R (0.98) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-9861601-B2 | Treatment of pulmonary arterial hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2827849-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142369-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142369-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | NR1H4 1045/4885LTB4R 3/4885LTB4R2 2/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | NR1H4 97/4885LTB4R 8/4885LTB4R2 7/4885 |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | NR1H4 1508/4885LTB4R 3/4885LTB4R2 2/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | NR1H4 97/4885LTB4R 8/4885LTB4R2 7/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | NR1H4 637/4885LTB4R 1/4885LTB4R2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.